Letermovir

Letermovir
Systematic (IUPAC) name
{(4S)-8-Fluoro-2-[4-(3-methoxyphenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetic acid
Clinical data
Legal status
  • Investigational
Routes of
administration
Oral
Identifiers
ATC code None
PubChem CID 45138674
ChemSpider 26352849
UNII 1H09Y5WO1F YesY
ChEMBL CHEMBL1241951
Synonyms AIC246
Chemical data
Formula C29H28F4N4O4
Molar mass 572.55 g/mol

Letermovir (INN) is an antiviral drug that is being developed for the treatment of cytomegalovirus (CVM) infections. It has been tested in CMV infected patients with allogeneic stem cell transplants and may also be useful for other patients with a compromised immune system such as those with organ transplants or HIV infections.[1]

The drug has been granted fast track status by the US Food and Drug Administration (FDA) and orphan drug status by the European Medicines Agency.[1]

The drug candidate is under development by Merck & Co., Inc as investigative compound MK-8828.[2]


References

  1. 1 2 "Neues Virostatikum Letermovir" (in German). Deutsche Apothekerzeitung. 2011-08-29.
  2. Masangkay, Estel Grace (July 29, 2014). "Merck Kicks Off Phase 3 Study Of CMV Drug Letermovir". Retrieved 8 Oct 2014.


This article is issued from Wikipedia - version of the Tuesday, March 24, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.